Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405244 · ClinicalTrials.gov registry record · Phase 3
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
A Phase 3 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT05405244 is a Phase 3 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 55 participants.
The verdict
NCT05405244, a Phase 3 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic predisposition that may markedly impact the effectiveness of this medication in those at high risk for T2DM.
Interventions
- DRUG Placebo
- DRUG Bromocriptine-QR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405244
The ClinicalTrials.gov registry entry for NCT05405244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05405244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05405244 about?
NCT05405244 is a clinical study titled "Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM". The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic pred...
What is the current status of trial NCT05405244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2017-09-19. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT05405244?
The interventions under investigation include: Placebo (DRUG), Bromocriptine-QR (DRUG).
Who is sponsoring clinical trial NCT05405244?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.